

# Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/M2E9DD17402EN.html>

Date: June 2020

Pages: 2289

Price: US\$ 2,500.00 (Single User License)

ID: M2E9DD17402EN

## Abstracts

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma - Pipeline Review, H1 2020, provides an overview of the Multiple Myeloma (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 10, 105, 118, 4, 10, 165, 29 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 19, 9, 32 and 8 molecules, respectively. Multiple Myeloma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Oncology).

The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Multiple Myeloma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Multiple Myeloma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Multiple Myeloma (Kahler Disease) - Overview

Multiple Myeloma (Kahler Disease) - Therapeutics Development

Multiple Myeloma (Kahler Disease) - Therapeutics Assessment

Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development

Multiple Myeloma (Kahler Disease) - Drug Profiles

Multiple Myeloma (Kahler Disease) - Dormant Projects

Multiple Myeloma (Kahler Disease) - Discontinued Products

Multiple Myeloma (Kahler Disease) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Aadi Bioscience Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by ABL Bio Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Acepodia Biotech Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Adicet Bio Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Agenus Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Allife Medical Science and Technology Co Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Allogene Therapeutics Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Ambrx Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Antengene Corp, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Arcellx Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Momenta Pharmaceuticals Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Multitude therapeutics Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Mustang Bio Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by SpecificiT Pharma Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pte Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by SpringWorks Therapeutics Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Starton Therapeutics Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Sunomix Therapeutics, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Suzhou Maximum Bio-tech Co Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by T-CURX GmbH, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by T-Knife GmbH, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by TaiGen Biotechnology Co Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Oncology Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Tiziana Life Sciences Plc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Tmunity Therapeutics Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Tolero Pharmaceuticals Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Triterpenoid Therapeutics Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Ube Industries Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Visterra Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Vycellix Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by WindMIL Therapeutics Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Wugen Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan YZY Biopharma Co Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by XEME BioPharma Inc, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Xiangxue Life Sciences, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by XNK Therapeutics AB, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Zhengda Tianqing Pharmaceutical Group Co Ltd, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline by Zovis Pharmaceuticals, H1 2020

Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2020

Multiple Myeloma (Kahler Disease) - Discontinued Products, H1 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

Aadi Bioscience Inc

AbbVie Inc

ABL Bio Inc

Acepodia Biotech Inc

Actinium Pharmaceuticals Inc

Active Biotech AB

Adicet Bio Inc

Aduro BioTech Inc

Aeglea BioTherapeutics Inc

Affimed GmbH

Agenus Inc

Alllife Medical Science and Technology Co Ltd

Allogene Therapeutics Inc

Ambrx Inc

Amgen Inc

Anhui Anke Biotechnology (Group) Co Ltd

Antengene Corp

APIM Therapeutics AS



APO-T BV  
Arcellx Inc  
Ariz Precision Medicine Inc  
Ascenta Therapeutics Inc  
Ascentage Pharma Group International  
Asclepius Technology Company Group Suzhou Co Ltd  
Aslan Pharmaceuticals Ltd  
AstraZeneca Plc  
Atara Biotherapeutics Inc  
Auransa Inc  
Aurigene Discovery Technologies Ltd  
Autolus Therapeutics Plc  
Ayala Pharmaceuticals Inc  
Bantam Pharmaceutical LLC  
Bayer AG  
Beijing Immunochina Medical Science & Technology Co Ltd  
Beijing Sunbio Biotech Co Ltd  
Bellicum Pharmaceuticals Inc  
Betta Pharmaceuticals Co Ltd  
BeyondSpring Inc  
BioLineRx Ltd  
Biomunex Pharmaceuticals  
Biosion Inc  
Biotest AG  
BioVec Pharma Inc  
BiVictriX Therapeutics Ltd  
Boehringer Ingelheim International GmbH  
Boryung ViGenCell Inc  
Boston Biomedical Inc  
Bristol-Myers Squibb Co  
CanBas Co Ltd  
Caribou Biosciences Inc  
CARsgen Therapeutics Ltd  
Cartesian Therapeutics Inc  
CASI Pharmaceuticals Inc  
CDR-Life Inc  
Cell Source Inc  
CellCentric Ltd  
Cellecstar Biosciences Inc

Collectis SA  
Celleron Therapeutics Ltd  
Cellestia Biotech AG  
Cello Therapeutics Inc  
Cellular Biomedicine Group Inc  
Celularity Inc  
Celyad Oncology  
Centrax International Inc  
Cerecor Inc  
Checkpoint Therapeutics Inc  
Chia Tai Tianqing Pharmaceutical Group Co Ltd  
Chipscreen Biosciences Ltd  
Chong Kun Dang Pharmaceutical Corp  
CiMaas BV  
Cleave Therapeutics Inc  
Constellation Pharmaceuticals Inc  
Corvus Pharmaceuticals Inc  
CRISPR Therapeutics AG  
CStone Pharmaceuticals Co Ltd  
Curis Inc  
Curocell Inc  
Cyclacel Pharmaceuticals Inc  
Cyteir Therapeutics Inc  
Cytonus Therapeutics Inc  
Cytovia Therapeutics Inc  
Daiichi Sankyo Co Ltd  
DC Prime BV  
DeuteRx LLC  
Diverse Biotech Inc  
Eli Lilly and Co  
Enceladus Pharmaceuticals BV  
EpicentRx Inc  
Epizyme Inc  
eTheRNA Immunotherapies NV  
Eureka Therapeutics Inc  
ExCellThera Inc  
Exelixis Inc  
F. Hoffmann-La Roche Ltd  
Fate Therapeutics Inc

Fera Pharmaceuticals LLC  
Fortis Therapeutics Inc  
Gadeta BV  
Galileo Research srl  
Gamida Cell Ltd  
GemoPharm  
Genenta Science srl  
Genentech Inc  
Genmab AS  
Geron Corp  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
Gliknik Inc  
GlycoMimetics Inc  
Glycostem Therapeutics BV  
GlyTR Therapeutics Inc  
GP Pharm SA  
Gracell Biotechnology Ltd  
GT Biopharma Inc  
Guangdong Zhongsheng Pharmaceutical Co Ltd  
HaemaLogix Pty Ltd  
Harbour BioMed  
Harpoon Therapeutics Inc  
Hebei Senlang Biotechnology Inc Ltd  
Heidelberg Pharma AG  
Helix BioPharma Corp  
Helocyte Biosciences Inc  
Hengenix Biotech Inc  
Hinova Pharmaceuticals Inc  
HitGen LTD  
HRAIN Biotechnology Co Ltd  
Hunan Siweikang Therapeutics Ltd  
HuniLife Biotechnology Inc  
Hutchison MediPharma Ltd  
iCell Gene Therapeutics LLC  
Ichnos Sciences Inc  
IDAC Theranostics Inc  
IDP Discovery Pharma SL  
IGM Biosciences Inc

ImmuneTarget Inc  
ImmunityBio Inc  
Immunomedics Inc  
Immunotech Biopharm Ltd  
Incuron LLC  
Incyte Corp  
Indapta Therapeutics Inc  
Inflection Biosciences Ltd  
Inmune Bio Inc  
Innovative Cellular Therapeutics Co Ltd  
Intra-Immug Pvt Ltd  
Inven2 AS  
Inventiva  
IO Biotech ApS  
Ionis Pharmaceuticals Inc  
Ionova Life Science Co Ltd  
Istesso Ltd  
Iterion Therapeutics  
Janpix Inc  
Jiangsu Hengrui Medicine Co Ltd  
JN Biosciences LLC  
Johnson & Johnson  
JSK Therapeutics Inc  
Jubilant Therapeutics Inc  
Juno Therapeutics Inc  
Juventas Cell Therapy Ltd  
JW Pharmaceutical Corp  
Kangpu Biopharmaceuticals Ltd  
Karyopharm Therapeutics Inc  
Kiadis Pharma NV  
Kleo Pharmaceuticals Inc  
Klyss Biotech Inc  
Komipharm International Co Ltd  
Kymab Ltd  
Laekna Therapeutics Shanghai Co Ltd  
Leadiant Biosciences Inc  
Les Laboratoires Servier SAS  
Leukogene Therapeutics Inc  
Ligand Pharmaceuticals Inc

Lokon Pharma AB  
Luye Pharma Group Ltd  
Mablink Bioscience  
Machavert Pharmaceuticals LLC  
Marker Therapeutics Inc  
Max Biopharma Inc  
MediGene AG  
MedPacto Inc  
Merck & Co Inc  
Merck KGaA  
Millennium Pharmaceuticals Inc  
Miltenyi Biotec GmbH  
MimiVax LLC  
Modulation Therapeutics Inc  
Molecular Partners AG  
Molecular Templates Inc  
MolMed SpA  
Momenta Pharmaceuticals Inc  
MorphoSys AG  
Multitude therapeutics Inc  
Mustang Bio Inc  
Mycovia Pharmaceuticals Inc  
Nanjing Bioheng Biotech Co Ltd  
Nanjing CART Medical Technology Co Ltd  
Nanjing Iaso Biotherapeutics Co Ltd  
Nanjing Legend Biotech Co Ltd  
NantKwest Inc  
Nektar Therapeutics  
Neonc Technologies Inc  
NewBay Medical Technology Co Ltd  
NexImmune Inc  
Northlake International LLC  
Novartis AG  
Noxxon Pharma AG  
Oncoceutics Inc  
Oncodesign SA  
OncoFusion Therapeutics Inc  
Oncolytics Biotech Inc  
Onconova Therapeutics Inc

OncoPep Inc  
Oncopeptides AB  
OncoTartis Inc  
OncoTherapy Science Inc  
One World Cannabis Ltd  
Ono Pharmaceutical Co Ltd  
Origincell Technology Group Co Ltd  
Otsuka Pharmaceutical Co Ltd  
PentixaPharm GmbH  
Pepton Inc  
PersonGen Anke Cellular Therapeutics Co Ltd  
PersonGen Biomedicine Suzhou Co Ltd  
Pfizer Inc  
Pharma Mar SA  
Phi Pharma SA  
Phosplatin Therapeutics LLC  
PI Therapeutics Ltd  
Pimera Inc  
Poseida Therapeutics Inc  
Precision Biosciences Inc  
Prescient Therapeutics Ltd  
Protheragen Inc  
Quadriga BioSciences Inc  
Qwixel Therapeutics LLC  
Rainier Therapeutics Inc  
Rapa Therapeutics LLC  
RAPT Therapeutics Inc  
RedHill Biopharma Ltd  
Regeneron Pharmaceuticals Inc  
Rhizen Pharmaceuticals SA  
Samus Therapeutics LLC  
Sanofi  
Seattle Genetics Inc  
SELLAS Life Sciences Group Inc  
Senhwa Biosciences Inc  
Shanghai Bioray Laboratory Inc  
Shanghai Theorion Pharmaceutical Co Ltd  
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd  
Shanghai Yingli Pharmaceutical Co Ltd

Shenogen Pharma Group Ltd  
Shuttle Pharmaceuticals Inc  
Sichuan Kelun Pharmaceutical Co Ltd  
SignalRx Pharmaceuticals Inc  
SignPath Pharma Inc  
Sorrento Therapeutics Inc  
SpecificiT Pharma Inc  
Spectrum Pharmaceuticals Inc  
Sphaera Pharma Pte Ltd  
SpringWorks Therapeutics Inc  
Starton Therapeutics Inc  
Sunomix Therapeutics  
Surface Oncology Inc  
Sutro Biopharma Inc  
Suzhou Maximum Bio-tech Co Ltd  
T-CURX GmbH  
T-Knife GmbH  
TaiGen Biotechnology Co Ltd  
Taiho Oncology Inc  
TaiRx Inc  
Takeda Pharmaceutical Co Ltd  
Targazyme Inc  
TeneoBio Inc  
Tiziana Life Sciences Plc  
Tmunity Therapeutics Inc  
Tolero Pharmaceuticals Inc  
Transgene Biotek Ltd  
Trillium Therapeutics Inc  
Triterpenoid Therapeutics Inc  
Ube Industries Ltd  
Vaccibody AS  
Vaxil Bio Therapeutics Ltd  
Vichem Chemie Research Ltd  
Visterra Inc  
Vycellix Inc  
Vyriad Inc  
WindMIL Therapeutics Inc  
Wugen Inc  
Wuhan Bio-Raid Biotechnology Co Ltd



Wuhan YZY Biopharma Co Ltd  
XEME BioPharma Inc  
Xiangxue Life Sciences  
XNK Therapeutics AB  
Zhengda Tianqing Pharmaceutical Group Co Ltd  
Zovis Pharmaceuticals

## I would like to order

Product name: Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/M2E9DD17402EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M2E9DD17402EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970